The value of the ICML and highlights from the 2017 Annual Congress
The introduction of biosimilar rituximab: a case study from the pharmacist's perspective
Novel methods to assess the effectiveness of chemotherapy in AML patients: MRD
A new era of treatment for elderly acute myeloid leukemia (AML) patients?
Hagop M. Kantarjian
Targeted therapies for CLL: new data and unanswered questions